RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $195 to $198.
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $195 to $198.